SpectraCure
2.325 SEK +1.09%1 investor is following this company
SpectraCure is a medical technology company The company specializes in the research and development of medical technology systems used to treat prostate cancer. The cancer treatments are based on proprietary systems that emit laser light sources and photoreactive drugs, a treatment methodology used for internally solid tumors of various types. The company operates in the Nordic market. The head office is located in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SPEC
Daily low / high price
2.23 / 2.345
SEK
Market cap
225.83M SEK
Turnover
121.56K SEK
Volume
53K
Financial calendar
Interim report
2024-08-15
Interim report
2024-11-14
Annual report
2025-02-20
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Masoud Khayyami | 10.0 % | 10.0 % |
Avanza Pension | 4.9 % | 4.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
SpectraCure AB (publ): Kvartalsrapport för januari – mars 2024
Positiv respons från urologer vid American Urological Associations konferens i San Antonio
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools